Viatris Inc. VTRS SPX
Company Overview
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Why Investors Should Care
Offers a dividend yield of 2.87%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $14.30B (-3.0% YoY); net profit $-3.51B.
- Trailing 12 Months Year-on-year growth — revenue +8.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -4.2%, profit CAGR -89.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -4.20% |
| 1 Year: | 8.10% |
Compounded Profit Growth
| 5 Years: | -89.70% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +85.48% |
| 6 Months: | +29.86% |
| 3 Months: | +18.80% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.87%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -4.2% CAGR over 5 years.
- Earnings shrank at -89.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VTRS Viatris Inc. SPX | 16.31 | -54.37 | $18.99B | 2.87% | -10.61% | -1.96% | -4.20% | -89.70% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.59B | 2.70B | 2.95B | 4.40B | 4.56B | 4.52B | 4.18B | 4.11B | 4.07B | 3.72B | 3.91B | 3.93B | 3.65B | 3.79B | 3.74B | 3.25B | 3.58B | 3.76B | 3.70B | 3.52B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09B | 2.25B | 2.39B | 2.56B | 2.36B |
| Gross Profit | - | - | 906.10M | 1.03B | 1.16B | 1.13B | 1.33B | 1.57B | 1.77B | 1.70B | 1.75B | 1.54B | 1.61B | 1.69B | 1.50B | 1.45B | 1.46B | 1.16B | 1.33B | 1.37B | 1.15B | 1.16B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17B | 1.15B | 1.14B | 1.31B | 1.18B |
| Operating Income | - | - | 184.70M | 134.20M | 351.40M | -266.20M | -47.80M | 357.60M | 707.40M | 548.70M | 560.10M | 399.80M | 369.20M | 451.70M | 203.90M | -239.90M | 225.90M | -8.90M | 185.40M | 234.50M | -157.50M | -20.20M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.32B | 577.80M | 800.20M | 543.40M | 548.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.50M | 116.60M | 119.60M | 119.60M | 120.10M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.10B | -217.10M | -7.90M | -343.00M | -247.30M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -55.00M | -212.50M | 120.30M | -2.90M | -423.70M |
| Net Income | 0 | 0 | 0 | -900.00K | -169.00M | - | - | - | - | - | - | - | - | - | - | - | - | -3.04B | -4.60M | -128.20M | -340.10M | 176.40M |
| Diluted EPS | - | - | 0.04 | 0.08 | 0.36 | -0.86 | -0.23 | 0.26 | 0.33 | 0.26 | 0.29 | 0.19 | 0.22 | 0.27 | 0.09 | -0.27 | 0.08 | -2.55 | 0.00 | -0.11 | -0.30 | 0.15 |
| R&D Expense | - | - | 114.20M | 156.30M | 129.80M | 184.10M | 147.70M | 152.10M | 142.30M | 162.60M | 174.90M | 182.90M | 208.30M | 211.20M | 199.70M | 204.10M | 198.40M | 222.00M | 218.80M | 250.40M | - | 248.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.27B | 11.37B | 11.82B | 17.81B | 16.26B | 15.43B | 14.74B | 14.30B |
| Cost of Revenue | - | - | - | - | 9.77B | 8.99B | 9.12B | 9.29B |
| Gross Profit | 4.00B | 3.90B | 3.80B | 5.58B | 6.50B | 6.44B | 5.62B | 5.01B |
| Operating Expenses | - | - | - | - | 4.84B | 4.88B | 4.91B | 4.76B |
| Operating Income | 905.60M | 715.50M | -210.80M | -34.00M | 1.66B | 1.56B | 710.30M | 253.50M |
| EBITDA | - | - | - | - | 6.43B | 3.52B | 2.82B | -395.40M |
| Interest Expense | - | - | - | - | 592.40M | 573.10M | 550.00M | 471.30M |
| Pretax Income | - | - | - | - | 2.81B | 202.90M | -623.20M | -3.67B |
| Tax Provision | - | - | - | - | 734.60M | 148.20M | 11.00M | -150.10M |
| Net Income | - | 0 | - | - | 2.08B | 54.70M | -634.20M | -3.51B |
| Diluted EPS | 0.68 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 |
| R&D Expense | 704.50M | 639.90M | 555.10M | 751.10M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Feb 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 31.26B | 61.55B | - | 50.02B | 47.69B | 41.50B | 37.19B |
| Current Assets | - | - | - | - | - | - | 10.64B | 12.98B | 9.52B | 9.79B |
| Cash & Equivalents | - | 388.10M | - | 475.60M | 844.40M | - | 1.26B | 991.90M | 734.80M | 1.32B |
| Inventory | - | - | - | - | - | - | 3.52B | 3.47B | 3.85B | 4.00B |
| Receivables | - | - | - | - | - | - | 3.24B | 2.82B | 2.68B | 2.58B |
| Total Liabilities | - | - | - | 19.37B | 38.60B | - | 28.95B | 27.22B | 22.87B | 22.48B |
| Current Liabilities | - | - | - | 5.57B | 10.56B | - | 6.75B | 7.78B | 5.78B | 7.09B |
| Long Term Debt | - | - | - | 11.21B | 22.43B | - | 18.02B | 16.19B | 14.04B | 12.48B |
| Total Debt | - | - | - | - | - | - | 19.53B | 18.37B | 14.31B | 14.70B |
| Total Equity | 13.31B | 12.17B | 0 | 0 | 22.95B | - | 21.07B | 20.47B | 18.64B | 14.71B |
| Shares Outstanding | - | - | - | - | - | - | 1.21B | 1.22B | 1.23B | 1.25B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.34B | 1.80B | 1.23B | - | 3.00B | 2.90B | 2.30B | 2.32B |
| Investing Cash Flow | -1.21B | -525.40M | -301.10M | - | 1.47B | -864.50M | 1.80B | -427.70M |
| Financing Cash Flow | -1.09B | -1.17B | -605.70M | - | -3.88B | -2.30B | -4.33B | -1.29B |
| Capital Expenditure | -252.10M | -213.20M | -243.00M | - | -489.40M | -574.90M | -359.10M | -465.10M |
| Free Cash Flow | 2.09B | 1.59B | 988.80M | - | 2.51B | 2.33B | 1.94B | 1.85B |
| Net Change in Cash | - | - | - | - | 595.20M | -266.40M | -226.80M | 594.30M |
| Share Buybacks | 432.00M | 0 | 0 | 0 | 0 | 250.00M | 250.00M | 500.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 35.5% | 34.3% | 32.1% | 31.3% | 40.0% | 41.7% | 38.2% | 35.1% |
| Operating Margin % | 8.0% | 6.3% | -1.8% | -0.2% | 10.2% | 10.1% | 4.8% | 1.8% |
| Net Margin % | - | 0.0% | - | - | 12.8% | 0.4% | -4.3% | -24.6% |
| ROE % | - | - | - | - | 9.9% | 0.3% | -3.4% | -23.9% |
| ROCE % | - | 2.8% | -0.4% | - | 3.8% | 3.9% | 2.0% | 0.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.24% | 84.36M | $1.42B |
| 2 | Davis Selected Advisers | 6.72% | 78.21M | $1.32B |
| 3 | Vanguard Capital Management LLC | 6.42% | 74.72M | $1.26B |
| 4 | Price (T.Rowe) Associates Inc | 5.66% | 65.86M | $1.11B |
| 5 | Vanguard Portfolio Management LLC | 4.63% | 53.91M | $906.52M |
| 6 | State Street Corporation | 4.49% | 52.23M | $878.31M |
| 7 | Dimensional Fund Advisors LP | 3.29% | 38.31M | $644.19M |
| 8 | Rubric Capital Management LP | 2.88% | 33.50M | $563.30M |
| 9 | Geode Capital Management, LLC | 2.73% | 31.85M | $535.49M |
| 10 | Invesco Ltd. | 1.89% | 21.97M | $369.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VTRS
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOSU5aNkU5SkpEMDZ1Uk8tWXVzeUJRcmd0aHR0RDhlOE9zbHh4b1Y5dzJjZWd2M3BhaXFDWHZXZlMyVTFtZ241MUR6akk1eEtydHhCdWJPdUs0Nmp6NmZyVUV3QktUNEtrUnRFY2V0cG9fVDhqZEVlWHV3SHhTWllpeUZLc21rS1hTV2JxcX…
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOLUdCcnhvb1ItdGFnMGViU0xJS2RTNHhMbWZXY0pQZzRzWEplTGhKSkZ2QVV1Nm5KdldjWi1ON3hSMVBSQTBST0ZIaWNlc0hTM2NPSUtBcW9UdWdZUkEtLWp3RXJ6dUFvT1VxX3ZIT1Y2clhHUlFiVlFqSzcwblQ2N2Z4Q25NWGowQ251Tn…
VTRS vs. DHR: Which Stock Is the Better Value Option? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNeFV2TjFrenZScGNZb2dlb1N0ZWlGVUVNblVuMktZNXRHZnM4Y2lHVjYtYUZ6WnktTWxScU52RzMtbVNuSEF3amthSGlpVFlCRWd1QjRTbTFvN0hFMkhLTnFwdFhrakVIbXpkcUM0U3puQVpzS0hmYktKRjJwYVhhNngyeXM3RFluM19BWk…
VTRS or DHR: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOSWhIOUlsc0N5R2tLSmJWQVplYmU2QzJSN3NGNGRkcUpiU2hSTlBaS015aXduTUI2eURfLXlUMTAwZ0JHVUlCeHp1NThjOEU5NV91cFFTZW41R1QtdTMzN1JFMUxQMmFPTzN2YkhNbFlJdkt0Y092ZlBGZkNnem96dG1VTkJjNEVZU3V0R0…
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPdm1EY1ItZDB2NHNVVVloYk1DSGNrdFNkT3pDX0xtRlIzWFRDUjVldDhhcGhIZndoT2dQbXh4MHRaNzE1RkdIODJkQXpsVVI2ZlZVVVN6NDV2bEYwdHFBSXgzQkQxQ1ItNU1mZTJjd0RndVZlc00zZXZtN1djNDE0Z2F4WDBLUXNzeXhpUH…
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQSF8tX0FQYm9VUzdLazA1bjhsMWNraV8wLVJGNnNxYk1Xemc4WUxiZGF6LXlRMjNJX0RpaHFreC1IalNYODhpN01PdXhib3NTeU9GY1l3Um5OLXVaZ18taFFFV1RoaFptOVZ5Vm52LTdCSUtIY2ljX2FNanR5TmNRR3BrUTRuOHJIUG5lUl…
VTRS — Frequently Asked Questions
What is the current share price of Viatris Inc. (VTRS)?
As of 2026-07-14 21:23 PDT, Viatris Inc. (VTRS) trades at $16.31 on NasdaqGS. Its 52-week range is $8.41 to $17.26.
What is the market capitalisation of VTRS?
Viatris Inc. (VTRS) has a market capitalisation of $18.99B on NasdaqGS.
What is the P/E ratio of VTRS?
VTRS trades at a trailing price-to-earnings (P/E) ratio of -54.37. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.34.
Does VTRS pay a dividend?
Viatris Inc. (VTRS) currently offers a dividend yield of 2.87%.
What is the return on equity (ROE) of VTRS?
VTRS has a return on equity (ROE) of -1.96%. Its return on capital employed (ROCE) is -10.61%.
Is VTRS a good stock to buy?
This page provides a data-driven analysis of Viatris Inc. (VTRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.